Natco Pharma Ltd. NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

In 2 Starfolio Baskets

Download real time

945.90 20.00 (2.16%)

29.46% Fall from 52W High

1.7M

NSE+BSE Volume

NSE 07 Jan, 2026 1:35 PM (IST)

Natco Pharma Corporate Filings & Announcements

Latest corporate announcements and filings from Natco Pharma on BSE

Search Inside the pdf :

Natco Pharma Ltd.

07 Jan 2026, 11:54AM

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Clarification

BSE India

Clarification

Natco Pharma Ltd.

07 Jan 2026, 11:04AM

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Clarification sought from Natco Pharma Ltd

BSE India

The Exchange has sought clarification from Natco Pharma Ltd on January 7, 2026, with reference to news appeared in https://economictimes.indiatimes.com/ dated January 7, 2026 quoting "HC seeks Novo Nordisk''s reply on Natco plea to revoke patent"The reply is awaited.

Natco Pharma Ltd.

06 Jan 2026, 04:32PM

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018

Natco Pharma Ltd.

05 Jan 2026, 05:05PM

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Sustainability Report For The Year 2024-25

BSE India

Sustainability Report for the year 2024-25

Natco Pharma Ltd.

29 Dec 2025

945.90

2.16%

SAST

Natco Pharma Ltd - 524816 - Closure of Trading Window

BSE India

Closure of Trading Window w.e.f. January 1, 2026

Natco Pharma Ltd.

02 Dec 2025

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Appointment of Mr. Amit Parekh as Executive Vice President - Finance & Accounts w.e.f. 2nd December, 2025

Natco Pharma Ltd.

29 Nov 2025

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation of Credit Rating

Natco Pharma Ltd.

21 Nov 2025

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Conclusion of USFDA inspection at our Manali, Chennai API unit

Natco Pharma Ltd.

20 Nov 2025

945.90

2.16%

Earnings Call

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Earnings call Transcript for the quarter and half year ended September 30, 2025 held on November 14, 2025

Natco Pharma Ltd.

15 Nov 2025

945.90

2.16%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication

Is Natco Pharma Ltd. worth buying?

601 Votes:

Buy 82.86%

Sell 7.49%

Hold 9.65%

RESEARCH REPORTS

Sell SEE REPORTS >

Hold SEE REPORTS >